429 related articles for article (PubMed ID: 17222678)
1. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S
J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678
[TBL] [Abstract][Full Text] [Related]
2. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
Yoshida A; Maruyama S; Fukumoto D; Tsukada H; Ito Y; Yamada S
Life Sci; 2010 Jul; 87(5-6):175-80. PubMed ID: 20598326
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
[TBL] [Abstract][Full Text] [Related]
5. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder.
Maruyama S; Oki T; Otsuka A; Shinbo H; Ozono S; Kageyama S; Mikami Y; Araki I; Takeda M; Masuyama K; Yamada S
J Urol; 2006 Jan; 175(1):365-9. PubMed ID: 16406943
[TBL] [Abstract][Full Text] [Related]
6. Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa.
Mansfield KJ; Chandran JJ; Vaux KJ; Millard RJ; Christopoulos A; Mitchelson FJ; Burcher E
J Pharmacol Exp Ther; 2009 Mar; 328(3):893-9. PubMed ID: 19029429
[TBL] [Abstract][Full Text] [Related]
7. Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice.
Ito Y; Oyunzul L; Yoshida A; Fujino T; Noguchi Y; Yuyama H; Ohtake A; Suzuki M; Sasamata M; Matsui M; Yamada S
Eur J Pharmacol; 2009 Aug; 615(1-3):201-6. PubMed ID: 19446545
[TBL] [Abstract][Full Text] [Related]
8. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.
Dmochowski R; Chen A; Sathyan G; MacDiarmid S; Gidwani S; Gupta S
J Clin Pharmacol; 2005 Aug; 45(8):961-8. PubMed ID: 16027408
[TBL] [Abstract][Full Text] [Related]
9. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
Oki T; Toma-Okura A; Yamada S
J Pharmacol Exp Ther; 2006 Mar; 316(3):1137-45. PubMed ID: 16282521
[TBL] [Abstract][Full Text] [Related]
10. In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin.
Oki T; Kawashima A; Uchida M; Yamada S
Life Sci; 2005 Apr; 76(21):2445-56. PubMed ID: 15763076
[TBL] [Abstract][Full Text] [Related]
11. In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice.
Yamada S; Maruyama S; Takagi Y; Uchida S; Oki T
Life Sci; 2006 Dec; 80(2):127-32. PubMed ID: 16996089
[TBL] [Abstract][Full Text] [Related]
12. Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder.
Yusup A; Akino H; Miwa Y; Oyama N; Aoki Y; Ito H; Tanase K; Matsuta Y; Nakai M; Yokoyama O
Eur J Pharmacol; 2007 Dec; 577(1-3):143-9. PubMed ID: 17904547
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model.
Naruganahalli KS; Sinha S; Hegde LG; Meru AV; Chugh A; Kumar N; Gupta JB; Ray A
Eur J Pharmacol; 2007 Oct; 572(2-3):207-12. PubMed ID: 17610864
[TBL] [Abstract][Full Text] [Related]
14. Tolterodine--a new bladder-selective antimuscarinic agent.
Nilvebrant L; Andersson KE; Gillberg PG; Stahl M; Sparf B
Eur J Pharmacol; 1997 May; 327(2-3):195-207. PubMed ID: 9200560
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
Ohtake A; Ukai M; Hatanaka T; Kobayashi S; Ikeda K; Sato S; Miyata K; Sasamata M
Eur J Pharmacol; 2004 May; 492(2-3):243-50. PubMed ID: 15178371
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
Gillberg PG; Sundquist S; Nilvebrant L
Eur J Pharmacol; 1998 May; 349(2-3):285-92. PubMed ID: 9671109
[TBL] [Abstract][Full Text] [Related]
17. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs.
Andersson SH; Lindgren A; Postlind H
Drug Metab Dispos; 1998 Jun; 26(6):528-35. PubMed ID: 9616187
[TBL] [Abstract][Full Text] [Related]
18. Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions.
Angelico P; Velasco C; Guarneri L; Sironi G; Leonardi A; Testa R
BMC Pharmacol; 2005 Oct; 5():14. PubMed ID: 16216132
[TBL] [Abstract][Full Text] [Related]
19. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
Ikeda K; Kobayashi S; Suzuki M; Miyata K; Takeuchi M; Yamada T; Honda K
Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):97-103. PubMed ID: 12122494
[TBL] [Abstract][Full Text] [Related]
20. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.
Oki T; Sato S; Miyata K; Yamada S
Br J Pharmacol; 2005 May; 145(2):219-27. PubMed ID: 15753946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
